Payment overview · 2025
General Payments
$1,551.11
89 reported records · 22 companies
Healthcare provider profile · identity verified
Sanjay J. Patel, MD
Allopathic & Osteopathic Physicians|Internal Medicine · FORT WAYNE, IN · NPI 1447227319
Verified facts
What the public records show
CMS Open Payments records show Sanjay J. Patel, MD received $1,551.11 in general payments during 2025 across 89 reported records.
ABBVIE INC. accounted for 15.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Gemtesa, Jardiance, Linzess, Mounjaro, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Adempas as an associated drug or biological on 3385 records involving 1868 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Adempas by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 132 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 135 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 197 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 171 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $243.22 | 15.7% | 17 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $166.39 | 10.7% | 17 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $154.26 | 9.9% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $137.47 | 8.9% | 9 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $129.22 | 8.3% | 7 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $93.03 | 6.0% | 4 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $72.87 | 4.7% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $62.66 | 4.0% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $56.38 | 3.6% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $54.84 | 3.5% | 3 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $53.82 | 3.5% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $46.09 | 3.0% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $45.22 | 2.9% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $34.66 | 2.2% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $32.94 | 2.1% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $29.87 | 1.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $27.24 | 1.8% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $26.89 | 1.7% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $26.56 | 1.7% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.97 | 1.6% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $16.31 | 1.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.20 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,551.11 | 89 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $166.39 | 17 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $140.28 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $120.45 | 8 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $118.61 | 8 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $102.47 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $93.03 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $88.49 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $85.90 | 7 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $85.90 | 7 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $77.79 | 4 | 2025 |
Source payment records
|
|||||
| Xolair Normalized: xolair |
Biological | Genentech USA, Inc. | $72.87 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $72.42 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $72.42 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $62.66 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $56.80 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $56.43 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $56.38 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $54.84 | 3 | 2025 |
Source payment records
|
|||||
| CDS - MCT/CEM Monitoring Normalized: cds mct cem monitoring |
Device | Boston Scientific Corporation | $53.82 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $46.09 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $45.22 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $42.66 | 4 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $38.71 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $34.66 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $32.94 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $27.24 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $27.24 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $26.89 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $24.97 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAMAX Normalized: vyndamax |
Drug | PFIZER INC. | $17.02 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $16.31 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.20 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $14.58 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 171 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 62 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 132 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 56 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 135 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 71 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
56 | 14 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
111 | 29 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
25 | 14 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
99 | 28 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
62 | 20 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Adempas open payments reported associated product |
CMS Open Payments — General Payments 3385 supporting records · 1868 recipient NPIs · example record 1225434673 |
Adempas · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
71 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
132 | 32 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
135 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
197 | 45 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
51 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
171 | 42 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1105 | 305 |
| Levothyroxine Sodium | Levothyroxine Sodium | 794 | 209 |
| Pantoprazole Sodium | Pantoprazole Sodium | 755 | 224 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 536 | 155 |
| Amlodipine Besylate | Amlodipine Besylate | 531 | 154 |
| Lisinopril | Lisinopril | 531 | 142 |
| Losartan Potassium | Losartan Potassium | 527 | 149 |
| Omeprazole | Omeprazole | 490 | 137 |
| Famotidine | Famotidine | 481 | 152 |
| Metoprolol Succinate | Metoprolol Succinate | 421 | 126 |
| Tamsulosin Hcl | Tamsulosin Hcl | 403 | 115 |
| Meloxicam | Meloxicam | 365 | 102 |
| Pravastatin Sodium | Pravastatin Sodium | 345 | 89 |
| Gabapentin | Gabapentin | 308 | 100 |
| Sertraline Hcl | Sertraline Hcl | 307 | 87 |
| Fluticasone Propionate | Fluticasone Propionate | 292 | 112 |
| Trazodone Hcl | Trazodone Hcl | 267 | 62 |
| Celecoxib | Celecoxib | 247 | 74 |
| Metformin Hcl | Metformin Hcl | 229 | 68 |
| Glimepiride | Glimepiride | 226 | 60 |
| Duloxetine Hcl | Duloxetine Hcl | 225 | 58 |
| Prednisone | Prednisone | 218 | 150 |
| Hydrochlorothiazide | Hydrochlorothiazide | 214 | 61 |
| Escitalopram Oxalate | Escitalopram Oxalate | 212 | 67 |
| Furosemide | Furosemide | 212 | 80 |
| Metformin Hcl Er | Metformin Hcl | 211 | 62 |
| Ozempic | Semaglutide | 197 | 45 |
| Bupropion Xl | Bupropion Hcl | 196 | 58 |
| Buspirone Hcl | Buspirone Hcl | 188 | 51 |
| Allopurinol | Allopurinol | 180 | 48 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 173 | 54 |
| Simvastatin | Simvastatin | 173 | 44 |
| Eliquis | Apixaban | 171 | 42 |
| Clopidogrel | Clopidogrel Bisulfate | 170 | 46 |
| Ezetimibe | Ezetimibe | 166 | 51 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 160 | 48 |
| Finasteride | Finasteride | 152 | 46 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 152 | 40 |
| Lovastatin | Lovastatin | 149 | 47 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 146 | 56 |
| Carvedilol | Carvedilol | 141 | 43 |
| Montelukast Sodium | Montelukast Sodium | 141 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 140 | 46 |
| Tramadol Hcl | Tramadol Hcl | 139 | 46 |
| Doxepin Hcl | Doxepin Hcl | 138 | 44 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 138 | 37 |
| Cephalexin | Cephalexin | 137 | 98 |
| Mounjaro | Tirzepatide | 135 | 27 |
| Jardiance | Empagliflozin | 132 | 32 |
| Potassium Chloride | Potassium Chloride | 132 | 57 |
| Citalopram Hbr | Citalopram Hydrobromide | 120 | 32 |
| Mirtazapine | Mirtazapine | 111 | 29 |
| Synthroid | Levothyroxine Sodium | 111 | 29 |
| Spironolactone | Spironolactone | 108 | 30 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 102 | 27 |
| Fluoxetine Hcl | Fluoxetine Hcl | 101 | 33 |
| Atenolol | Atenolol | 99 | 28 |
| Myrbetriq | Mirabegron | 99 | 28 |
| Quetiapine Fumarate | Quetiapine Fumarate | 98 | 22 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 85 | 27 |
| Donepezil Hcl | Donepezil Hcl | 80 | 27 |
| Januvia | Sitagliptin Phosphate | 79 | 25 |
| Alendronate Sodium | Alendronate Sodium | 77 | 23 |
| Doxycycline Hyclate | Doxycycline Hyclate | 76 | 46 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 72 | 22 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 71 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 71 | 21 |
| Amitriptyline Hcl | Amitriptyline Hcl | 70 | 18 |
| Chlorthalidone | Chlorthalidone | 70 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 70 | 28 |
| Tresiba Flextouch U-100 | Insulin Degludec | 69 | 16 |
| Solifenacin Succinate | Solifenacin Succinate | 65 | 25 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 65 | 14 |
| Farxiga | Dapagliflozin Propanediol | 62 | 20 |
| Lansoprazole | Lansoprazole | 58 | 23 |
| Ropinirole Hcl | Ropinirole Hcl | 58 | 15 |
| Azelastine Hcl | Azelastine Hcl | 57 | 21 |
| Azithromycin | Azithromycin | 57 | 50 |
| Linzess | Linaclotide | 56 | 14 |
| Memantine Hcl | Memantine Hcl | 56 | 13 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 55 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 54 | 15 |
| Ipratropium Bromide | Ipratropium Bromide | 53 | 11 |
| Lamotrigine | Lamotrigine | 53 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 53 | 15 |
| Xarelto | Rivaroxaban | 53 | suppressed |
| Clonazepam | Clonazepam | 52 | suppressed |
| Rybelsus | Semaglutide | 51 | 13 |
| Ibandronate Sodium | Ibandronate Sodium | 50 | 16 |
| Aripiprazole | Aripiprazole | 49 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 48 | 15 |
| Irbesartan | Irbesartan | 47 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 46 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 45 | 22 |
| Methocarbamol | Methocarbamol | 44 | 16 |
| Topiramate | Topiramate | 44 | 18 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 42 | 13 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 42 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 41 | 13 |
| Sucralfate | Sucralfate | 41 | 16 |
| Valsartan | Valsartan | 41 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 40 | 13 |
| Nystatin | Nystatin | 40 | 27 |
| Diclofenac Sodium | Diclofenac Sodium | 38 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 38 | suppressed |
| Alprazolam | Alprazolam | 37 | 16 |
| Estradiol | Estradiol | 37 | 11 |
| Glipizide | Glipizide | 37 | suppressed |
| Klor-Con M20 | Potassium Chloride | 37 | 20 |
| Methylprednisolone | Methylprednisolone | 36 | 34 |
| Ondansetron Odt | Ondansetron | 36 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 35 | 32 |
| Sumatriptan Succinate | Sumatriptan Succinate | 35 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 35 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 35 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 34 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 33 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 33 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | 13 |
| Clonidine Hcl | Clonidine Hcl | 32 | suppressed |
| Fluconazole | Fluconazole | 32 | 21 |
| Testosterone Cypionate | Testosterone Cypionate | 32 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 22 |
| Glipizide Er | Glipizide | 30 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 30 | 22 |
| Pioglitazone Hcl | Pioglitazone Hcl | 30 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 29 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 29 | 11 |
| Repaglinide | Repaglinide | 29 | suppressed |
| Trulicity | Dulaglutide | 28 | suppressed |
| Cefdinir | Cefdinir | 27 | 24 |
| Dutasteride | Dutasteride | 27 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 27 | suppressed |
| Primidone | Primidone | 27 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | 11 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 25 | 11 |
| Enalapril Maleate | Enalapril Maleate | 25 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 25 | suppressed |
| Pregabalin | Pregabalin | 25 | 13 |
| Prolia | Denosumab | 25 | 14 |
| Amoxicillin | Amoxicillin | 24 | 14 |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 13 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 20 |
| Lorazepam | Lorazepam | 23 | 11 |
| Hydrocortisone | Hydrocortisone | 22 | 14 |
| Sildenafil Citrate | Sildenafil Citrate | 21 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 20 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 20 | suppressed |
| Lidocaine | Lidocaine | 20 | suppressed |
| Metronidazole | Metronidazole | 20 | 17 |
| Midodrine Hcl | Midodrine Hcl | 20 | suppressed |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 20 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Naproxen | Naproxen | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Torsemide | Torsemide | 19 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Calcitriol | Calcitriol | 18 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | 12 |
| Bumetanide | Bumetanide | 17 | suppressed |
| Folic Acid | Folic Acid | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 16 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 16 | suppressed |
| Telmisartan | Telmisartan | 16 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 16 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | 13 |
| Mometasone Furoate | Mometasone Furoate | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 14 | suppressed |
| Repatha Syringe | Evolocumab | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 13 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Fluorouracil | Fluorouracil | 13 | 12 |
| Movantik | Naloxegol Oxalate | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | 12 |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Adempas | Riociguat | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Gemtesa | Vibegron | 11 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 11 | suppressed |
| Humulin R | Insulin Regular, Human | 11 | suppressed |
| Invokana | Canagliflozin | 11 | suppressed |
| Keppra | Levetiracetam | 11 | suppressed |
| Tegretol | Carbamazepine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,551.11 · 89 records | ABBVIE INC. | AIRSUPRA, Auvelity, BREZTRI, CDS - MCT/CEM Monitoring, CREON, Dexcom G6 Transmitter, ELIQUIS, FANAPT, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, GVOKE HYPOPEN, JARDIANCE, Kerendia, Korlym, LEQVIO, LINZESS, MOUNJARO, NURTEC ODT, OTEZLA, QULIPTA, REPATHA, REXULTI, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR, VYNDAMAX, Veozah, Wegovy, Xolair, ZAVZPRET, ZEPBOUND | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error